COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme
26/11/2018
Bagsværd, Denmark, 26 November 2018 - On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
26/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
ITL Pharma Receives United States Patent Protection for Carcinin® Using Halogenated Phenol Ethers for Diagnostics, Antioxidant Protection and Drug Delivery
26/11/2018
KINGSPORT, Tenn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- ITL Pharma, Inc. (ITL), a LIAS Company, today announced awarding of a United States Patent allowance (S.N. 15/336,179) titled: "Halogenated Phenols for Diagnostic, [...]
Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting
26/11/2018
Full Results from Second Pivotal Phase 3 Trial of FINTEPLA ® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503) Studies on the Impact of Severe [...]
Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
26/11/2018
Data Expected in Second Half of 2019 CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO) (“Evelo”) a clinical-stage biotechnology company developing monoclonal microbials to engage [...]
SoldierStrong Announces 2018 SoldierScholar Recipients
26/11/2018
STAMFORD, Conn., Nov. 26, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical technologies to veterans, today announced the 2018 recipients of its SoldierScholar [...]
InMode Receives Notice from the FDA of Satisfactory Address of the FDA Letter
26/11/2018
LAKE FOREST, Calif. and YOKNEAM, Israel, Nov. 26, 2018 (GLOBE NEWSWIRE) -- InMode Ltd. announced today that the FDA has advised the company of satisfactory address of all items that appeared in the ‘It Has Come to Our [...]
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
26/11/2018
CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced [...]
Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium
26/11/2018
NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will present clinical [...]
Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline
26/11/2018
Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operations Parag Meswani, Pharm.D., formerly head of U.S. [...]
CareDx Announces Full Repayment of its Outstanding Debt
26/11/2018
Recent Equity Financing Leads to Strong, Debt-Free Balance Sheet BRISBANE, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and [...]
HempAmericana Estimates $1M Revenue Yield from First Hemp Harvest at Its Union Farm Facility
26/11/2018
NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – HempAmericana, Inc. (OTC: HMPQ) (“HempAmericana” or the “Company”) is excited to announce production results and revenue estimates following the first [...]
Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
26/11/2018
PLYMOUTH MEETING, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that three recent published studies of its DNA-Encoded monoclonal antibody (dMAb™) technology showed [...]
Spectral Announces Publication of the post hoc analysis of EUPHRATES trial in Intensive Care Medicine
26/11/2018
TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT) , a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a [...]
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
26/11/2018
Company to provide regulatory filing status update FRAMINGHAM, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid [...]
CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments
26/11/2018
CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor PLEASANTON, Calif. and HANGZHOU, China, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT) and Zhejiang [...]
Antares Pharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
26/11/2018
EWING, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 30 th Annual Piper Jaffray Healthcare [...]
CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals
26/11/2018
OXNARD, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement [...]
Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
26/11/2018
SAN DIEGO and TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of [...]

Pages